First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Investigational Site Number :0360002, Melbourne

Investigational Site Number :0360001, Melbourne

Weill Cornell Medical College-Site Number:8400003, New York

Montefiore Hutchinson Campus- Site Number : 8400012, The Bronx

Investigational Site Number :2500002, Marseille

The Children's Hospital of Philadelphia- Site Number : 8400013, Philadelphia

Emory University School of Medicine- Grady Campus- Site Number : 8400006, Atlanta

The Ohio State University- Site Number : 8400009, Columbus

Investigational Site Number :2500001, Paris

Investigational Site Number : 2500004, Paris

MD Anderson Cancer Center-Site Number:8400001, Houston

City of Hope-Site Number:8400002, Duarte

Investigational Site Number :2500003, Villejuif

Oregon Health and Science University-Site Number:8400011, Portland

Seattle Children's Hospital- Site Number : 8400014, Seattle

Investigational Site Number : 1560001, Tianjin

Investigational Site Number : 1560003, Zhengzhou

Beth Israel Deaconess Medical Center-Site Number:8400004, Boston

Children's Hospital of Philadelphia-3401 Civic Center Blvd Site Number : 8400013, Philadelphia

Investigational Site Number :5280002, Amsterdam

Investigational Site Number :5280003, Groningen

Investigational Site Number : 5280005, Nijmegen

Investigational Site Number :5280001, Rotterdam

Investigational Site Number :5280004, Utrecht